RED® 72 SILVER LABEL is our latest large-bore Reperfusion Catheter, which provides the highest TRF on the marketa and is optimized for navigating challenging anatomy in LVO.

  • RED Reperfusion Catheters (RED 72 SILVER LABEL, RED 72 SILVER LABEL with SENDit® Technology, RED 68, and RED 62) are intended for use in the revascularization of patients with acute ischemic stroke. Every case is different, and the RED family of catheters provides a full range of products designed to optimize lumen size and trackability for the situation. All five products feature new REDglide Technology, which is designed to improve catheter interaction with vessels and to enhance delivery in tortuosity.

    • SILVER LABEL Technology: Blended transition zones designed for enhanced performance in challenging anatomy
    • .072″ (1.83 mm) Lumen: Delivers highest TRFa
    • .085″ (2.16 mm) Outer Diameter: Articulating marker band design to improve tip softness
    • REDglide Technology: Enhanced distal hydrophilic coating for smooth trackability
    • 132 cm Length: To reach target vessels

    a. As compared to AXS Vecta™ 71 and Stryker® (Medela), LBC and Vacuson 60, React™ 71 and Riptide™, AXS Vecta 74 and Stryker (Medela), and Zoom™ 71 and Zoom pump. Thrombus Removal Force (TRF) = (Catheter Tip Area) × (Vacuum). Sources: company website, marketing literature, IFU, and data on file.

    • Delivers and maintains nearly pure vacuum (-29.2 inHg or -98.88 kPa)b
    • Simple setup
    • Integrated clot catcher
    • Disposable Penumbra ENGINE® Canister
    • Compatible with all Penumbra System® Reperfusion Catheters

    b. Data on file at Penumbra, Inc.

The REDglide Difference

RED 72 vs JET 7

Resources

  • Document Icon

    In the News

    Read our latest news, articles, and posts.

  • Document Icon

    Meetings & Events

    View our conference and event schedule.

  • Document Icon

    Therapies & Conditions

    Learn more about how our products are used for a broad spectrum of conditions.

  • Document Icon

    Clinical Evidence

    Access the latest clinical research and data.

Questions?

Contact us to learn more about our products and company